Immediate emergency care (call 911) is necessary if you experience: Signs of severe allergic reaction (anaphylaxis): difficulty breathing, severe swelling of face or throat, rapid heartbeat, severe dizziness, or widespread rash Symptoms suggesting pancreatitis: severe, persistent abdominal pain that may radiate to the back, often accompanied by nausea and vomiting Signs of thyroid tumor: new lump or swelling in the neck, hoarseness, difficulty swallowing, or shortness of breath Contact your healthcare provider within 24 hours for: Persistent injection site reactions lasting more than a few days, including significant redness, swelling, hardness, or pain Signs of infection at the injection site: increasing warmth, red streaking, pus, or fever Severe or persistent gastrointestinal symptoms (nausea, vomiting, diarrhea) that interfere with eating or hydration Symptoms of hypoglycemia (if taking semaglutide with insulin or sulfonylureas): excessive sweating, shakiness, confusion, rapid heartbeat, or extreme hunger Changes in vision or eye pain, especially if you have a history of diabetic retinopathy Symptoms of gallbladder problems: pain in the upper right abdomen, fever, yellowing of skin or eyes, clay-colored stools Unexplained rapid heartbeat or palpitations Signs of kidney problems: significant changes in urination, swelling in legs or feet, unusual fatigue Routine follow-up is appropriate for: Questions about proper injection technique or site rotation Mild, transient injection site reactions that resolve within a day General questions about medication storage or handling Difficulty with pen operation or concerns about dose delivery Your healthcare provider should monitor your response to semaglutide through regular follow-up appointments, typically including assessment of glycemic control (for diabetes treatment), weight changes, and potential adverse effects
THANK YOU Feeling amazing Fast service Quick delivery
For the first time since I was 12 years old, my brain is just...quiet
Weeks 5 through 12: As the dose increases, appetite suppression becomes more pronounced
At 10 mg/mL, you are at 2.0 mg, nearly the full maintenance dose
SURMOUNT-5 Head-to-Head In 2025, Eli Lilly published the SURMOUNT-5 trial directly comparing tirzepatide (15 mg) and semaglutide (2.4 mg) in adults with obesity over 72 weeks
